CJC-1295 and ipamorelin: what is in it and does it work?

What is in the CJC-1295 and ipamorelin blend?

CJC-1295 and ipamorelin contains CJC-1295 and Ipamorelin. Most products sold under this name pair ipamorelin with modified GRF (1-29), usually labeled CJC-1295 without DAC, rather than the long-acting CJC-1295 with DAC that was tested in trials. They are different molecules with very different half-lives. Amounts and ratios vary by seller, and research-chemical labels are not verified. PeptideAgent does not name or link sellers.

Also searched as: CJC-1295 ipamorelin; CJC-1295/ipamorelin blend; CJC ipamorelin; Ipamorelin CJC-1295; Mod GRF 1-29 and ipamorelin.

Grades and statuses come from each peptide's own record and update with it. Grades follow the methodology.

Why are these peptides combined in the CJC-1295 and ipamorelin blend?

The pairing rests on real physiology. Growth hormone release is driven by two pathways: GHRH acting on its own receptor, and ghrelin-like signals acting on the growth hormone secretagogue receptor. In a 1990 study of 18 healthy men, a single intravenous dose of GHRH given with a synthetic ghrelin receptor hexapeptide released more growth hormone than either alone, a synergy that suggested the two act independently.

Sellers extend that finding to CJC-1295 and ipamorelin. But the 1990 study used different molecules, single intravenous doses, and a one-hour hormone readout. It says nothing about repeated injections, body composition, or the safety of the pair sold today. [1] [2] [3]

Has the CJC-1295 and ipamorelin blend been studied?

No published study has tested CJC-1295 with ipamorelin in humans or animals, and PubMed indexes no trial of the pair.

CJC-1295 alone has small randomized trials in healthy adults: a single injection raised mean growth hormone 2 to 10 fold for 6 or more days and IGF-1 1.5 to 3 fold for 9 to 11 days. Those trials measured hormones only, not muscle, fat, sleep, or any clinical outcome, and development was discontinued.

Ipamorelin's only randomized human trial gave it intravenously after bowel surgery and found no significant difference from placebo in time to the first tolerated meal. One small human pharmacology study showed a single IV infusion releases growth hormone in healthy men, but no human study reports growth hormone, IGF-1, or body composition with the injections sold today. [1] [3] [6] [14]

What each ingredient has shown alone

• CJC-1295 (human RCT evidence). Long acting lab-made growth hormone releasing hormone: small randomized trials raised GH 2 to 10 fold and IGF-1 1.5 to 3 fold per dose; no lawful compounding.
• Ipamorelin (animal-only evidence). Growth hormone releaser acting on the hunger hormone (ghrelin) receptor; raised GH in animals and one small study in men; its only randomized trial failed.

CJC-1295 and ipamorelin results and before and after claims

People searching for CJC-1295 and ipamorelin results often ask how long it takes to see changes in muscle, fat, or sleep. No study has measured those outcomes for the pair or for either peptide alone, so there is no evidence-based timeline.

What has been measured is hormones: CJC-1295 raises growth hormone and IGF-1 in healthy adults. Higher IGF-1 is not the same as more muscle or less fat. The GHRH analog with measured body composition results is tesamorelin, which reduced visceral fat in trials in HIV lipodystrophy, and that result does not transfer to other peptides.

A 2026 review of growth hormone axis peptides used outside medical care describes the uncertainty around product composition, dose, and stacking in unregulated supply, and the resulting uncertainty about claimed body recomposition benefits. Before and after photos cannot resolve it. [3] [4] [8]

What are the side effects of the CJC-1295 and ipamorelin blend?

No study has recorded the side effects of the combination. In CJC-1295 trials the common effects were injection site reactions, flushing, headache, and transient warmth, and FDA cited increased heart rate and a systemic vasodilatory reaction among serious adverse events when it evaluated CJC-1295 for its Category 2 list.

Raising growth hormone through two routes at once could add up effects such as water retention, joint aches, tingling, higher blood glucose, and increased appetite from ghrelin receptor activation. A 2026 review of growth hormone axis peptides lists prolactin and cortisol rises, appetite changes, blood glucose problems, fluid retention, muscle and joint pain, and injection site reactions among reported adverse effects.

FDA also cited immunogenicity risk from aggregation and impurities when it placed ipamorelin on the Category 2 list in 2023. Long-term effects of sustained IGF-1 elevation, including on existing tumors, have not been studied. [3] [8] [10]

Reported for each ingredient

From each peptide's record. These were reported for the peptide alone, not for the blend. Absence of data is not evidence of safety.

Is the CJC-1295 and ipamorelin blend legal?

A blend inherits the strictest status among its ingredients, because a mixed product is only as lawful as its least lawful component. For the CJC-1295 and ipamorelin blend that is CJC-1295 and Ipamorelin: no lawful path. At least one ingredient cannot be lawfully compounded or prescribed, so no licensed pharmacy can lawfully make the mix.

• CJC-1295 regulatory timeline (Removed from Category 2 (Apr 2026))
• Ipamorelin regulatory timeline (Removed from Category 2 (Apr 2026))

Why blends like this are sold as research chemicals

A drug for human use in the United States has to be FDA approved or lawfully compounded by a licensed pharmacy for a named patient under a prescription. This blend can be neither, so vials sold under its name carry labels such as “for research use only” or “not for human consumption”. That label does not make a product lawful to inject, and it means no one has checked the vial for identity, purity, sterility, or amount. [11]

WADA status

CJC-1295 and Ipamorelin are prohibited at all times on the WADA list, so any product containing them is prohibited for athletes subject to anti-doping testing.

State rules: peptide laws by state. All FDA actions: regulatory tracker.

What does the CJC-1295 and ipamorelin blend cost, and what can a provider lawfully offer?

Neither peptide has a lawful path. FDA placed CJC-1295 and ipamorelin on the 503A Category 2 list in September 2023; the nominations were later withdrawn, and FDA's April 2026 update lists both as nominated but withdrawn rather than on the bulks list. Neither was reviewed at the July 2026 advisory committee meeting, and neither is a component of an approved drug.

Licensed 503A pharmacies and 503B outsourcing facilities therefore have no lawful basis to compound either peptide, alone or combined, and there is no lawful price. Advertised prices come from research-chemical sellers and clinics.

The one GHRH analog in the catalog with FDA approval is tesamorelin (Egrifta), approved to reduce excess abdominal fat in adults with HIV lipodystrophy. It is a different molecule with its own label, and it can be prescribed. [9] [10] [11] [12]

• CJC-1295 cost by channel
• Ipamorelin cost by channel
• Rules by state
• Verified provider directory

What's actually offered, and what that means for you

Licensed compounding pharmacies, clinics, and telehealth prescribers openly offer many unapproved peptides, and prescribers write prescriptions for them. That does not make the CJC-1295 and ipamorelin blend lawful. CJC-1295 and ipamorelin are not FDA approved and not on the 503A bulks list, so no pharmacy has a lawful basis to compound the mix. [10] [11]

Enforcement is uneven. FDA mostly acts through warning letters to compounders and online sellers, Category 2 safety listings, and import alerts that let it detain shipments, rather than stopping every pharmacy. State pharmacy boards oversee pharmacies day to day, and their rules differ. [10] [15] [16] [17] [18]

What changes for you

• No FDA review of the product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [18]
• Identity, purity, sterility, and dose accuracy can vary from batch to batch. [10]
• Insurance rarely covers it, so you usually pay cash.
• For tested athletes, the CJC-1295 and ipamorelin blend contains at least one ingredient that is prohibited at all times on the WADA list. [13]

What to check

These checks lower some risks, but they do not make an unlawfully compounded product lawful or safe. Check for:

• A 503A pharmacy licensed in your state (your state board of pharmacy publishes license lookups). [18]
• A real evaluation by a licensed prescriber, not just an online form.
• A certificate of analysis for the specific batch.

Compare the ingredients

• CJC-1295 vs ipamorelin
• Ipamorelin vs GHRP-6
• Ipamorelin vs MK-677 (ibutamoren)
• Sermorelin vs CJC-1295
• Sermorelin vs ipamorelin

Blends that share an ingredient

• Sermorelin and ipamorelin: Sermorelin and ipamorelin pair a formerly approved GHRH fragment with a ghrelin mimetic. The pair is untested, and ipamorelin has no lawful path.
• Tesamorelin and ipamorelin: Tesamorelin is FDA approved as Egrifta; ipamorelin has no lawful path. Mixed together they are untested and cannot be lawfully compounded.

Frequently asked questions

From the blog

• CJC-1295 side effects: what the human studies reported

  CJC-1295 side effects in small human studies included injection site reactions, headache, flushing, diarrhea, and a faster heart rate. It has no FDA approval and no lawful compounding path.

• Peptide stacks: what each common component has shown alone

  No trial has tested a multi-peptide stack for muscle growth or fat loss. Nine common stack components ranked by their own human evidence, legal status, and WADA status. No protocols.

• How to get peptides prescribed legally in 2026

  Which peptides a licensed prescriber can lawfully write for today, which are waiting on an FDA rule, how telehealth rules work, and the red flags that mean a product is not a prescription at all.

• Peptides for muscle growth, ranked by human evidence

  MK-677, sermorelin, tesamorelin, CJC-1295, IGF-1 LR3, and more ranked by human evidence. None is approved for muscle growth, and all ten are banned in tested sport.

• Tesamorelin vs sermorelin vs ipamorelin: evidence and legality

  Tesamorelin, sermorelin, and ipamorelin compared in one table: mechanism, FDA approval, compounding status, human evidence, and WADA status, with links to each pairwise comparison.

• What is peptide therapy? What clinics sell, what is legal, and what works

  Peptide therapy means three different things: FDA-approved drugs, compounded prescriptions, and research-only products. Here is how to tell them apart, what the evidence shows, and what it costs.

Sources

Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.